Abstract
The target of rapamycin (TOR) is a highly conserved protein kinase and a central controller of cell growth. In budding yeast, TOR is found in structurally and functionally distinct protein complexes: TORC1 and TORC2. A mammalian counterpart of TORC1 (mTORC1) has been described, but it is not known whether TORC2 is conserved in mammals. Here, we report that a mammalian counterpart of TORC2 (mTORC2) also exists. mTORC2 contains mTOR, mLST8 and mAVO3, but not raptor. Like yeast TORC2, mTORC2 is rapamycin insensitive and seems to function upstream of Rho GTPases to regulate the actin cytoskeleton. mTORC2 is not upstream of the mTORC1 effector S6K. Thus, two distinct TOR complexes constitute a primordial signalling network conserved in eukaryotic evolution to control the fundamental process of cell growth.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Loewith, R. et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457–468 (2002).
Wedaman, K.P. et al. Tor kinases are in distinct membrane-associated protein complexes in Saccharomyces cerevisiae. Mol. Biol. Cell 14, 1204–1220 (2003).
Jacinto, E. & Hall, M.N. Tor signalling in bugs, brain and brawn. Nature Rev. Mol. Cell Biol. 4, 117–126 (2003).
Hara, K. et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177–189 (2002).
Kim, D.H. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163–175 (2002).
Kim, D.H. et al. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11, 895–904 (2003).
Harris, T. E. & Lawrence, J.C. TOR signaling. Sci. STKE 15, 1–17 (2003).
Gingras, A.C., Raught, B. & Sonenberg, N. mTOR signaling to translation. Curr. Top. Microbiol. Immunol. 279, 169–197 (2004).
Brunn, G.J. et al. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15, 5256–5267 (1996).
Sarkaria, J.N. et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59, 4375–4382 (1999).
Davies, S.P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105 (2000).
Ridley, A.J. Growth factor-induced actin reorganization in Swiss 3T3 cells. Methods Enzymol. 256, 306–313 (1995).
Schaller, M.D. Paxillin: a focal adhesion-associated adaptor protein. Oncogene 20, 6459–6472 (2001).
Etienne-Manneville, S. & Hall, A. Rho GTPases in cell biology. Nature 420, 629–635 (2002).
Fingar, D.C. & Blenis, J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151–3171 (2004).
Xia, Y. et al. Mammalian target of rapamycin and protein kinase A signaling mediate the cardiac transcriptional response to glutamine. J. Biol. Chem. 278, 13143–13150 (2003).
Lamb, R.F. et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nature Cell Biol. 2, 281–287 (2000).
Astrinidis, A. et al. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 21, 8470–8476 (2002).
Schmidt, A., Bickle, M., Beck, T. & Hall, M.N. The yeast phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2. Cell 88, 531–542 (1997).
Chou, M.M. & Blenis, J. The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1. Cell 85, 573–583 (1996).
Fang, Y. et al. PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1. Curr. Biol. 13, 2037–2044 (2003).
Peterson, R.T., Beal, P.A., Comb, M.J. & Schreiber, S.L. FKBP12–rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J. Biol. Chem. 275, 7416–7423 (2000).
Oshiro, N. et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9, 359–366 (2004).
Dos, D.S. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296–1302 (2004).
Hubberstey, A., Yu, G., Loewith, R., Lakusta, C. & Young, D. Mammalian CAP interacts with CAP, CAP2, and actin. J. Cell. Biochem. 61, 459–466 (1996).
Ridley, A.J., Paterson, H.F., Johnston, C.L., Diekmann, D. & Hall, A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70, 401–410 (1992).
Dennis, P. B. et al. Mammalian TOR: a homeostatic ATP sensor. Science 294, 1102–1105 (2001).
Brummelkamp, T.R., Bernards, R. & Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550–553 (2002).
Azim, A.C., Barkalow, KL.. & Hartwig, J.H. Determination of GTP loading on Rac and Cdc42 in platelets and fibroblasts. Methods Enzymol. 325, 257–263 (2000).
Notredame, C., Higgins, D.G. & Heringa, J. T-Coffee: A novel method for fast and accurate multiple sequence alignment. J. Mol. Biol. 302, 205–217 (2000).
Acknowledgements
We thank A. Löschmann and W. Oppliger for technical assistance, A. Lorberg and N. Kralli for helpful discussions, R. Shioda for help with alignments and P. Houghton, G. Thomas and D. Sabatini for providing reagents. This work was supported by grants from the Cancer Research Institute (E.J.), the European Molecular Biology Organization (R.L.), Cancer Research UK (A.S. and A.H.) and the Canton of Basel and the Swiss National Science Foundation (M.N.H. and M.R.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Information, Figures
Fig. S1, Fig. S2, Fig. S3, Fig. S4 (PDF 267 kb)
Rights and permissions
About this article
Cite this article
Jacinto, E., Loewith, R., Schmidt, A. et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6, 1122–1128 (2004). https://doi.org/10.1038/ncb1183
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb1183
This article is cited by
-
Splenic proteome profiling in response to Marek’s disease virus strain GX0101 infection
BMC Veterinary Research (2024)
-
The role of TSC1 and TSC2 proteins in neuronal axons
Molecular Psychiatry (2024)
-
mTORC1 in energy expenditure: consequences for obesity
Nature Reviews Endocrinology (2024)
-
mTOR Plays an Important Role in the Stemness of Human Fetal Cartilage Progenitor Cells (hFCPCs)
Tissue Engineering and Regenerative Medicine (2024)
-
The role of prickle proteins in vertebrate development and pathology
Molecular and Cellular Biochemistry (2024)